Table 2.
Association of VKORC1 and CYP2C9 SNPs with Warfarin Sensitivity during the Stabilization Phase of Therapy of 139 Cardiovascular Patients Treated with Warfarin.
| Gene | SNP ID | Genotype | Sensitivea | Moderateb | Resistancec | P-value* |
|---|---|---|---|---|---|---|
| VKORC1 | rs10871454 | CC | (1/28) 3.6% | (10/28) 35.7% | (17/28) 60.7% | <0.001 |
| CT | (5/69) 7.2% | (51/69) 73.9% | (13/69) 18.8% | |||
| TT | (14/42) 33.3% | (25/42) 59.5% | (3/42) 7.1% | |||
| rs8050894 | CC | (1/26) 3.8% | (9/26) 34.6% | (16/26) 61.5% | <0.001 | |
| CG | (5/69) 7.2% | (50/69) 72.5% | (14/69) 20.3% | |||
| GG | (14/44) 31.8% | (27/44) 61.4% | (3/44) 6.8% | |||
| rs9934438 | CC | (2/28) 7.2% | (10/28) 35.7% | (16/28) 57.1% | <0.001 | |
| CT | (5/71) 7.0% | (53/71) 74.6% | (13/71) 18.3% | |||
| TT | (14/40) 35.0% | (23/40) 57.5% | (3/40) 7.5% | |||
| rs17708472 | CC | (20/106) 18.8% | (68/106) 64.2% | (18/106) 17.0% | 0.003 | |
| CT | (1/30) 3.3% | (17/30) 56.7% | (12/30) 40.0% | |||
| TT | (1/3) 33.3% | (0/3) 0.0% | (2/3) 66.7% | |||
| CYP2C9 | rs1799853 | CC | (14/105) 13.3% | (65/105) 61.9% | (26/105) 24.8% | 0.654 |
| CT | (7/32) 21.9% | (18/32) 56.2% | (7/32) 21.9% | |||
| TT | (0/2) 0.0% | (2/2) 100.0% | (0/2) 0.0% | |||
| rs4086116 | CC | (6/77) 7.8% | (46/77) 59.7% | (25/77) 32.5% | 0.007 | |
| CT | (13/53) 24.5% | (32/53) 60.4% | (8/53) 15.1% | |||
| TT | (2/9) 22.2% | (7/9) 77.8% | (0/9) 0.0% | |||
| rs1057910 | AA | (11/108) 10.2% | (66/108) 61.1% | (31/108) 28.7% | 0.001 | |
| AC | (10/31) 32.3% | (20/31) 64.5% | (1/31) 3.2% | |||
*
Chi-square test with p value < 0.05 is considered significant.
a
Warfarin Sensitive group (required minimum warfarin dose < 21 mg/week).
b
Warfarin Moderate response group (required average warfarin dose between 21 and 49 mg/week).
c
Warfarin Resistance group (required high warfarin dose > 49 mg/week).